Oncology
An expanding next-generation sequencing (NGS) oncology portfolio is helping Illumina drive the revolution in cancer genomics. Our NGS and microarray technologies are among the most trusted in the world. Our sample-to-data solutions deliver high-quality, reproducible results to speed the discovery and analysis of cancer-related variants—and potentially transform the cancer care cycle.
We’re committed to advancing and individualizing the way cancer will be identified and treated. We want to partner with you in helping propel progress in personalized oncology. Together we can work toward achieving our ultimate goal: to make discoveries that will make a life-changing difference to cancer patients and their loved ones.
Illumina panels
TruSight Hereditary Cancer Panel
- Extensive panel includes 113 genes associated with hereditary cancer predisposition
- Easy protocol enables fast and flexible library prep and enrichment
- Compatibility with all Illumina benchtop sequencing systems with sample throughput ranging from 2 to 256 samples per run
- Hybrid–capture enrichment enables good coverage uniformity for accurate detection of SNVs, indels, and CNVs
Trusight Oncology 500
- TruSight Oncology 500 (TSO 500) is an NGS assay that enables in-house comprehensive genomic profiling (CGP) from FFPE tissue
- Targets 523 genes to assess all DNA and RNA variant types (single nucleotide variants, copy number variants, indels, and fusions), plus microsatellite instability (MSI), tumor mutational burden (TMB), and homologous recombination deficiency (HRD)†
- Delivers accurate results with hybrid–capture chemistry and sophisticated bioinformatics
- Reduces hands-on time with optional automation kits and methods*
- Also available in a high-throughput configuration
*Not available for TSO 500 HRD.
†HRD is only available with the addition of the TruSight Oncology 500 HRD kit to TruSight Oncology 500. Not available in Japan.
‡Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
- Targets 523 genes to assess all DNA and RNA variant types (SNV, CNV, indels, fusions), plus MSI and TMB
- Delivers accurate results with hybrid–capture chemistry and sophisticated bioinformatics
- Reduces hands-on time and increases scalability with optional automation kits and methods*
- Accommodates 8-36 samples with the NextSeq 1000 and NextSeq 2000 Systems, 16-192 samples with the NovaSeq 6000 System, and 32-960 samples with the NovaSeq X Series per run
* Automation available on the Beckman Coulter iSeries or the Hamilton Microlab STAR. Contact Illumina Sales for more information.
†Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
- Leverage low cfDNA inputs (20 ng) from minimally invasive blood samples to achieve sensitive and accurate detection (0.2% VAF for SNVs) using UMI-based hybrid-capture library prep and deep sequencing.
- Target 523 genes to assess DNA variants across major variant classes (SNV, MNV, indels, CNV, and gene rearrangements), plus key immuno-oncology gene signatures (TMB, MSI)
- Expansion to NovaSeq X Series offers transformative economics, faster sequencing run times by close to 40% and broader batch sizes (4-48 samples)
- Streamlined workflow with advanced chemistry and automation-friendly kits and method enables a single-day library prep plus enrichment and total turnaround time of 3-4 days.
- DRAGEN secondary analysis powers a rapid variant calling algorithm on-premises or in the cloud with Illumina Connected Analytics. Access insights using integrated reporting with Illumina Connected Insights* or Velsera.
*Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
Pillar Biosciences panels
Pillar OncoReveal Essential MPN Panel
The oncoReveal Essential MPN Panel is a robust NGS assay that simultaneously tests for key mutations within the MPL, JAK2, and CALR genes. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
Pillar OncoReveal Essential MPN Panel
The oncoReveal Multi-Cancer with CNV & RNA Fusion Panel is a combined DNA/RNA multi-cancer panel. The assay combines the DNA-based oncoReveal Multi-Cancer v4 with CNV Panel with the oncoReveal Multi-Cancer RNA Fusion v2 Panel allowing for joint sequencing. The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
Variants and CNVs detected from DNA
Pillar OncoReveal Myeloid Panel
The oncoReveal Myeloid Panel is a robust NGS assay that interrogates 58 genes of interest* most relevant to myeloid cancers. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
oncoReveal Myeloid Panel (58 genes)
Pillar OncoReveal BRCA1 and BRCA2 plus CNV Panel
The oncoReveal BRCA1 & BRCA2 plus CNV Panel is designed for the detection of exon-level copy number variation (CNV) across the entire coding region of the BRCA1 and BRCA2 genes. The assay is designed with shorter amplicons to allow for detection of mutations from FFPE samples, while also being compatible with intact genomic DNA from blood samples. The assay sequences the full coding region plus 10bp of flanking introns. The panel utilizes proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
Pillar OncoReveal Core LBx Panel
The oncoReveal Core LBx panel is a robust NGS assay that interrogates 104 genes of interest* across multiple solid tumor cancer types. The panel is specifically designed for cell-free DNA (cfDNA) extracted from plasma and can detect four types of variants: single nucleotide variants (SNVs), small insertion/deletion (indel) variants, copy number amplification (CNA), and microsatellite instability (MSI). The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
Pillar OncoReveal Essential LBx Panel
The oncoReveal Essential LBx panel is a robust NGS assay that interrogates 197 targets across 34 genes of interest* from multiple solid tumor cancer types. This is a focused panel that can detect four types of variants from cell-free DNA (cfDNA) that has been extracted from plasma: single nucleotide variants (SNVs), small insertion/deletion (indel) variants, copy number amplification (CNA), and microsatellite instability (MSI). The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
*Content is based on data from ongoing clinical trials along with sources that include the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), the National Comprehensive Cancer Network (NCCN), and the Catalog of Somatic Mutations in Cancer (COSMIC) database.
Pillar OncoReveal Fusion LBx Panel
The oncoReveal Fusion LBx panel is a robust NGS assay that interrogates multiple gene rearrangement regions of interest across multiple solid tumor cancer types. The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube enrichment of targets from cell-free RNA extracted from plasma.
Pillar OncoReveal Solid Tumor v2 Panel
The oncoReveal Solid Tumor v2 Panel is a robust 48-gene assay that simultaneously tests for key mutations present in solid tumors, including NSCLC, colorectal, melanoma, endometrial, pancreatic, GIST, bladder, thyroid, and gliomas. Additionally, genes with potential importance in immuno-oncology such as POLD1 and POLE are analyzed. The panel uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
oncoReveal Multi-Cancer RNA Fusion v2 panel
The oncoReveal Multi-Cancer RNA Fusion v2 Panel is a robust NGS assay that interrogates multiple gene rearrangement regions of interest* across multiple solid tumor cancer types. The assay uses proprietary Stem-Loop Inhibition-Mediated amplification (SLIMamp®) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.